2 weeks Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates Zacks

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -15.38% and 0.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?